Core Viewpoint - Zhiyan Zhaowu (Shaoxing) Biotechnology Co., Ltd. is a high-tech enterprise driven by artificial intelligence and synthetic biology innovation, focusing on the integration of AI technology with biological manufacturing to advance biotechnological progress and commercialization [1][3]. Company Overview - Founded in 2020 in Silicon Valley, Cardinal Biocraft has developed an AI-driven synthetic biology platform, investing over 50 million yuan and establishing a leading research and development platform for synthetic biological strains [1]. - The company has established three major R&D centers in California, Hefei, and Hangzhou, and aims to create a comprehensive R&D, production, and operation center in Shaoxing by 2024 [1]. Core Advantages - The company utilizes AI algorithms to accelerate gene design, metabolic pathway optimization, and strain modification, overcoming traditional R&D efficiency bottlenecks and enabling rapid conversion from laboratory to industrial production [3]. - It focuses on large-scale biological manufacturing needs, developing low-cost and high-stability biological synthesis solutions to empower green biological manufacturing [3]. Talent Acquisition - The company is seeking talented individuals in the fields of synthetic biology and industrial biotechnology, including positions for assistant researchers, fermentation engineers, and research assistants [4][7][12]. - Candidates are expected to have strong professional knowledge and experience in areas such as enzyme and metabolic pathway optimization, high-throughput strain screening, and fermentation process scaling [9][11][13]. Upcoming Events - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and biological manufacturing, and exploring trends in the bio-manufacturing industry [14][15].

Core Insights - The 2024 annual report performance briefing series for the biopharmaceutical industry on the Sci-Tech Innovation Board has commenced, focusing on new drug development, overseas business expansion, and future development strategies as key investor concerns [1] Group 1: New Drug Development - The company plans to increase its R&D investment, with a total of 70.41 million yuan in 2024, representing a year-on-year increase of 26.25%. The company is conducting Phase III clinical trials for its antidepressant JJH201501 and Phase IIa trials for its anti-tumor drug JJH201601 [2] - The company aims to complete the Phase III clinical research and new drug application for JJH201501 by the end of 2025, leveraging existing product channels for commercialization [2] - The company has established a professional R&D team of over 100 members and is focusing on innovative drug research, particularly first-class innovative drugs [2] Group 2: Future R&D Strategy - The company intends to enhance its R&D strategy by targeting major disease markets and utilizing a combination of in-house development, external collaborations, acquisitions, and product licensing to enrich its product pipeline [3] - The company is focusing on developing first-in-class antibody drugs, which carry high risks but could lead to revolutionary treatment breakthroughs [3] - The integration of artificial intelligence in drug development is seen as a new trend to improve efficiency and quality [4] Group 3: Overseas Business Expansion - The overseas business has become a focal point, with the company achieving good results in both domestic and international markets, particularly in the EU market for its albumin paclitaxel product [4] - The company plans to leverage its established overseas commercialization platform to introduce new products and drive sales, aiming for a 200% to 400% increase in overseas sales revenue by 2025 compared to 2023 [5] - The company will focus on high-tech barrier products in key markets and expedite the registration and market launch of introduced products [5] Group 4: Business Outlook - The company is committed to optimizing its product structure and enhancing operational efficiency while focusing on high-value-added product lines [6] - The company will continue to increase R&D investment and improve its management systems to ensure sustainable growth [6] - The company aims to implement an "AI + synthetic biology" strategy and pursue international development, leveraging digitalization and intelligence for high-quality, sustainable growth [7]